An Introduction to Multiple Sclerosis
Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the CNS and one of the most common causes of neurological disability in adults. It is characterized by a relapsing-remitting clinical course, which progresses to a more chronic progressive phase, although a minority have a progressive course from onset. Numerous disease-modifying therapies (DMTs) have emerged, including oral (fingolimod, dimethyl fumarate, teriflunomide, cladribine, siponimod, ozanimod), injectable (glatiramer acetate, pegylated interferon beta-1a) and intravenous (alemtuzumab, ocrelizumab) options. Challenges include switching therapies in patients who become refractory to initial treatment. MS is also the fastest growing indication for autologous haematopoietic stem cell transplantation in Europe, with a growing body of evidence supporting its use in highly active relapsing-remitting MS that does not respond to DMTs.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Multiple Sclerosis Content
Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study
Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]
Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis
The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the aim, designs and outcomes of these studies as well as the subpopulation analyses […]
Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis
The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the unmet needs of this population and the mechanism of action of ublituximab. The […]
Highlights from EAN 2023!
Paradoxical Tumefactive Worsening of Multiple Sclerosis After Natalizumab Initiation: A Case Report
touchREVIEWS in Neurology. 2023;19(2):Online ahead of journal publication
Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination and neurodegeneration. Natalizumab is a widely used anti-α4 integrin inhibitor for treating highly active MS. In the pivotal trials of natalizumab for MS, the SENTINEL and AFFIRM trials, natalizumab was established to reduce the rate of clinical relapses and […]
Individualizing long-term treatment and care in active MS: How are therapeutic sequencing options evolving to address unmet needs?
Two experts in MS explore the practicalities of therapeutic sequencing options in MS
- Evaluate factors guiding the use of high-efficacy DMTs in the management of active MS
- Summarize current approaches and safety considerations relating to DMT switching and sequencing in MS
- Appraise the use of DMTs in women of child-bearing age with MS, including considerations for family planning and implications during pregnancy and beyond
Updates in Paediatric Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
touchREVIEWS in Neurology. 2023;19(1): DOI: https://doi.org/10.17925/USN.2023.19.1.36
Acute disseminated encephalomyelitis (ADEM), first characterized in 1931,1 is a non-specific clinical syndrome of polyfocal central nervous system (CNS) inflammatory demyelination; it is characterized by encephalopathy and large, poorly demarcated cerebral white matter lesions.2,3 Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), a specific neuronal antibody-mediated disease that can often present as ADEM, was discovered only in the last decade.4 Both […]
Understanding the pathophysiology of multiple sclerosis and the development of new therapies
Prof. Tobias Derfuss reviews the cellular model of disease in multiple sclerosis, and how pathophysiology can offer novel therapeutic targets.
- Explain the cellular model of disease in multiple sclerosis
- Explain how the pathobiology of multiple sclerosis drives the development of disease-modifying therapies
- Summarize the mechanism of action of Bruton’s tyrosine kinase inhibitors and how this may translate into clinical benefits for patients with multiple sclerosis
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!